In the study, the amount of glucose being metabolized was measured using the well established hyperinsulinemic euglycemic clamp model. Specifically, animals treated with DM-99 were able to use 41% more glucose than an untreated animal (p less than 0.04) during the first 60 minutes of the study.
Karl-Gunnar Hidinger, president of DiaMedica, said: “Based upon the collective results of our preclinical studies, we have already initiated the regulatory clearance process for a Phase II human study with DM-99 and expect to receive feedback in the near term. We plan to test DM-99 as a stand-alone therapy in a meal-tolerance model.”